Extraordinary General Meeting of Meda Aktiebolag (publ)

At the request of Mylan N.V., which after completion of its public offer to the shareholders of Meda Aktiebolag (“Meda” or the “Company”) owns more than nine-tenths of the shares in Meda, the shareholders of Meda are hereby invited to attend the Extraordinary General Meeting on Thursday August 25, 2016 at 3 p.m. on Meda’s premises at Pipers väg 2A, Solna, Sweden.

Right to participate

Shareholders who wish to participate shall:

both               be registered in the share register held by Euroclear Sweden AB on Friday August                       19 2016, and

and                send notice of their intention to participate to Meda by Friday, August 19 2016.

In order to be entitled to vote at the Extraordinary General Meeting, shareholders whose shares are registered in the names of nominees must temporarily register their shares in their own names with Euroclear Sweden AB by Friday, August 19, 2016. Consequently, shareholders should notify nominees well in advance of that date.

Notification of attendance

Notice of Extraordinary General Meeting participation shall be given via mail to Meda AB, EGM, Box 7835, SE-103 98 Stockholm, Sweden, via phone at +46-8-402 90 49, or on the company’s website www.meda.se. In the notice the shareholder’s name, Swedish civil registration number or corp.reg.no, address, number of shares, phone number (daytime), and information about accompanying assistants (no more than two) shall be stated. If participating by proxy, please submit the original proxy document to Meda before the Extraordinary General Meeting. The expiry date of the proxy document may be no more than five years from its issuance. If the proxy is issued by a legal entity, a certified copy of the registration certificate for the legal entity must also be submitted. The proxy form is available at www.meda.se, and will be sent to shareholders who request the form and specify an address.

Proposal for agenda

At the Extraordinary General Meeting, the following matters will be dealt with.

1. Opening of the EGM

2. Election of the EGM chairman

3. Establishment and approval of the voting list

4. Approval of the agenda

5. Election of one or two persons to verify the minutes

6. Determination of whether the EGM was duly convened

7. Determination of the number of board members and deputy board members to be appointed

8. Determination of board remuneration

9. Election of board members and chairman of the board

10. Closing of the EGM

Proposed resolutions

Item 7-9: proposed board members and remuneration

The Company has been informed that Mylan N.V., holding more than 90 percent of the shares and votes in the company as at the date of this notice, proposes the following:

that                the board shall consist of three ordinary board members and no alternate members;

that                no remuneration shall be paid to the board members for the board assignments;

that                the following Mylan group executives are elected as new board members,

                                            - Caroline Dixon, born 1968; Head of Finance, Northern Europe

                                            - Jacek Glinka, born 1963; President, Europe

                                            - Colleen Ostrowski, born 1973; Treasurer; and

that                Jacek Glinka is elected as chairman of the board.

Further information

At the time of publication of this notice, the number of shares and votes in Meda total 365,467,371. Only class A shares have been issued. The company holds no own shares.

On the request of a shareholder the board of directors and the CEO shall provide information at the EGM concerning conditions that could influence the assessment of an item on the agenda, provided that the board deems that disclosure is possible without causing material damage to the company.

Solna, Sweden, August 2016

The board of directors

Meda AB (publ)

For further inquiries, please contact:

Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599                                                                                                                                                                                                                  paula.treutiger@meda.se

This press release was submitted for publication 17:00 p.m. CET on 2 August 2016.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.